Variants in KCNQ2 encoding for K v 7.2 neuronal K + channel subunits lead to a spectrum of neonatal-onset epilepsies, ranging from self-limiting forms to severe epileptic encephalopathy. Most KCNQ2 pathogenic variants cause loss-of-function, whereas few increase channel activity (gain-of-function). We herein provide evidence for a new phenotypic and functional profile in KCNQ2-related epilepsy: infantile spasms without prior neonatal seizures associated with a gain-of-function gene variant. With use of an international registry, we identified four unrelated patients with the same de novo heterozygous KCNQ2 c.593G>A, p.Arg198Gln (R198Q) variant. All were born at term and discharged home without seizures or concern of encephalopathy, but developed infantile spasms with hypsarrhythmia (or modified hypsarrhythmia) between the ages of 4 and 6 months. At last follow-up (ages 3-11 years), all patients were seizure-free and had severe developmental delay. In vitro experiments showed that Kv7.2 R198Q subunits shifted current activation gating to hyperpolarized potentials, indicative of gain-of-function; in neurons, K v 7.2 and K v 7.2 R198Q subunits similarly populated the axon initial segment, suggesting that gating changes rather than altered subcellular distribution contribute to disease molecular pathogenesis. We conclude that KCNQ2 R198Q is a model for a new subclass of KCNQ2 variants causing infantile spasms and encephalopathy, without preceding neonatal seizures.
Variants in the KCNQ2 gene are responsible for a wide phenotypic spectrum of epileptic diseases, ranging from benign familial neonatal epilepsy (BFNE; OMIM: 121200) to neonatal-onset epileptic encephalopathy (EIEE7; OMIM: 613720). 1 In autosomal-dominant KCNQ2-BFNE, seizures start in otherwise healthy infants around the first week of life and spontaneously disappear after a few months, with mostly normal interictal electroencephalography (EEG), neuroimaging findings, and psychomotor development. By contrast, EIEE7 is nearly always caused by de novo KCNQ2 missense variants, and characterized by multiple, pharmacoresistant seizures beginning in the first few days of life, burst-suppression pattern or multifocal epileptiform activity on EEG, and moderate to severe developmental impairment.
2,3 KCNQ2 pathogenic variants are among the most common cause for neonatal-onset EE, overlapping with Ohtahara syndrome and early myoclonic encephalopathy.
1
KCNQ2 encodes for K v 7.2 K + channel subunits underlying the neuronal voltage-gated M-current (I KM ). 4 Most KCNQ2 pathogenic variants decrease channel function, with stronger functional impairment often causing more severe epileptic phenotypes. 5, 6 In addition, a few EIEE7 de novo variants enhance channel function. 7, 8 Genotype-phenotype correlations are difficult to establish in rare disorders due to interfamilial and intrafamilial phenotypic variability; comparing histories of patients carrying the same KCNQ2 pathogenic variant provides the unique opportunity to correlate the specific variant with the disease clinical course and severity. Herein, we describe the case histories of four unrelated patients carrying the same de novo KCNQ2 missense variant (c.593G>A) leading to the p.R198Q substitution. All patients exhibited similar clinical courses, characterized by infantile spasms (IS) without previous neonatal seizures. In vitro, when compared to wild-type, mutant K v 7.2 R198Q channels activated at less-depolarizing potentials, thus showing a gain-of-function (GOF) effect.
Methods

Clinical database
The Rational Intervention for KCNQ2/3 Epileptic Encephalopathy (RIKEE) database is currently edited and maintained at Baylor College of Medicine under an institutional review board (IRB)-approved research protocol. RIKEE collects information about patients where genetic tests show KCNQ2 and KCNQ3 sequence variants, their phenotypes, and related lab studies; summaries are disclosed on a website (www.rikee.org). For each patient reported here, the registering parent optionally consented to be re-contacted by study staff. A study neurologist (ECC, JJM) reviewed proband and parental Clinical Laboratory Improvement Amendments (CLIA)-certified genetics lab reports to confirm genotypes, reviewed medical charts, and interviewed a parent to resolve uncertainties in the medical record.
Heterologous expression and whole-cell electrophysiology
Variants were introduced using site-directed mutagenesis into human KCNQ2 complementary DNA (cDNA); channel subunits were expressed in Chinese Hamster Ovary (CHO) cells by transient transfection, as described 5 (Data S1). Currents were recorded under whole-cell patch-clamp at room temperature (20-22°C) 1-2 days after transfection.
Multistate structural modeling
Three-dimensional models of K v 7.2 subunits were generated by using as templates the coordinates of six different states of K v 1.2/2.1 paddle chimera (PDB accession number 2R9R; 29% of sequence identity with K v 7.2) obtained in molecular dynamics simulations, 9 as described previously (Data S1). 5 
Neuronal cell transfection and immunocytochemistry
The subcellular distribution of K v 7.2 subunits was investigated in primary cultures of rat hippocampal neurons transfected with dually epitope tagged (hemagglutinin and enhance green fluorescent protein) KCNQ2 (wild-type or mutant) and KCNQ3 (encoding K v 7.3) cDNAs. The axon initial segment (AIS)/soma and AIS/dendrite ratios were calculated from confocal images as described in the Supplementary Methods section (Data S1), as reported. 10 
Statistics
Data are expressed as the mean AE standard error of the mean (SEM). The Student's t-test was used for statistical comparison (p < 0.05).
Results
Clinicogenetic data
In all four patients, genetic testing performed as part of clinical care revealed a heterozygous c.593G>A, p.R198Q variant in the KCNQ2 gene (Table 1) ; this variant is not found in healthy subjects (http://exac.broadinstitute.org/ gene/ENSG00000075043). All parents were found to be negative for the KCNQ2 R198Q variant. All four patients in the RIKEE database carrying the KCNQ2 c.593G>A, p.R198Q variants were included.
In addition to the KCNQ2 c.593G>A, p R198Q variant, all four patients had additional variants of uncertain significance in other epilepsy-related genes that were not considered clinically significant based on the currently available information. These were the following: TSC2 (c.599+3 A>G; heterozygous), CLN5 (c.127G>A; heterozygous), and PRICKLE1 (c.425 C>T; heterozygous) for patient 1; PCDH19 (c.1321G>C; hemizygous) and PPT1 (c.904 A>G; heterozygous) for patient 2; NDUFAF2 (c.221G>A; heterozygous; paternally inherited; autosomal recessive) for patient 3; and RET (c.2556 C>G; heterozygous; maternally inherited) for patient 4.
Patient characteristics
All four patients were born at term and discharged home from the nursery without seizures or concern of encephalopathy. Onset of IS with hypsarrhythmia (or modified hypsarrhythmia) occurred between the ages of 4 and 6 months ( Table 1) .
Patient 1
At 5 months, parents noticed regression marked by decreased smiling and increased irritability. At 6 months, clusters of IS characterized by neck flexion and limb extension began. Initially, about two clusters per day (25 spasms per cluster) occurred. EEG obtained at the local hospital showed a modified hypsarrhythmia pattern. Initial treatment (topiramate and levetiracetam) was incompletely effective. Video-EEG at age 6 months captured numerous clusters of flexor IS and a modified hypsarrhythmia pattern consisting of generalized background slowing and multifocal epileptiform discharges (Fig. S1A ). For ongoing spasms, oral prednisone was given, producing a complete but temporary remission. Clobazam was started while topiramate was down titrated. She was diagnosed with KCNQ2 encephalopathy at 8-months-old and ezogabine was added to oxcarbazepine, clobazam, and levetiracetam. Ezogabine was titrated to 13 mg/kg/day that resulted in an initial improvement in seizures and alertness that was not sustained. Due to recurrence of refractory IS, combinations of ezogabine, levetiracetam, oxcarbazepine, carbamazepine, and clobazam were tried. EEG background at 18-monthsold was significant for diffuse background slowing (Fig. S1B) . By the time the patient was 2 years old, seizures stopped on a combination of carbamazepine, ezogabine, clobazam, and levetiracetam. Anticonvulsants were serially weaned off. At last follow-up (3 years old), she remains seizure free on carbamazepine monotherapy. She has severe developmental delay and is unable to speak or sit.
Patient 2
At 4 months, parents noted episodes of trunk flexion that occurred multiple times per day and were associated with irritability. Video-EEG showed background activity consistent with hypsarrhythmia and captured electroclinical IS. Oral prednisolone was started. Spasms stopped immediately and hypsarrhythmia resolved within 1 month. He was started on zonisamide, but was subsequently changed to levetiracetam due to side effects. Last available EEG study showed a continuous background with diffuse slowing and multifocal epileptiform discharges. At last follow-up (3 years old), he remains seizure free on levetiracetam monotherapy. Development was slow for the first 2 years of life, and at 3 years old he is able to babble and sit unassisted.
Patient 3
At 4 months there was parental concern for developmental regression, including loss of babbling, smiling, and rolling. Shortly thereafter, parents noted clusters of bilateral arm extension associated with irritability. EEG was performed, showing hypsarrhythmia. The patient was treated with adrenocorticotropic hormone (ACTH) producing a temporary remission. However, spasms recurred. Subsequent treatments included topiramate, zonisamide, levetiracetam, and vigabatrin. Ultimately, spasms ceased after ketogenic diet was started at 10 months old. The patients was weaned off all anticonvulsants after several months of seizure freedom. Ketogenic diet was discontinued 4 months later and she remained seizure-free off anticonvulsants since then. At age 5 years, she has global developmental delay, is nonverbal, and cannot sit unassisted.
Patient 4
At 3-4 months, parents noted developmental regression in the form of loss of head control, and paroxysmal events characterized by blank staring and unresponsiveness for 10-15 s associated with upward eye deviation and slight hand movements. At 6 months, an initial EEG performed for "jerks" was significant for a severely abnormal background that was discontinuous with asynchronous bursts of high-amplitude epileptiform discharges. Seizures were treated with levetiracetam and the parent reported a good response. After two episodes of prolonged seizures in early childhood, she has remained seizure free on continued levetiracetam since age 6. EEG studies at 7-9 years old showed diffuse slowing. At age 11 years, she has global developmental delay, is attentive, but cannot speak or sit unassisted.
Functional properties and neuronal subcellular localization of channels incorporating K v 7.2 R198Q subunits
The c.593G>A variant substitutes the highly conserved, most extracellular, positively charged arginine (R1) with a neutral glutamine (Q) (p.R198Q, Fig. 1A ) along the fourth transmembrane segment S 4 (Fig. 1B) . In CHO cells, K v 7.2 channels generated K + -selective and voltage-dependent currents that activated around À40 mV (Fig. 1C) . At the holding voltage of À80 mV, homomeric K v 7.2 channels are closed; therefore, the ratio between the current measured at the beginning of the depolarizing step (I inst ) and that at the end of the 0 mV depolarization (I steady-state ), was negligible (0.02 AE 0.01). Homomeric K v 7.2 R198Q channels displayed a 30 mV hyperpolarizing shift in their activation gating (Fig. 1C,D) , and the I inst /I steady-state ratio was 0.26 AE 0.02 due to the presence of a large fraction of channels already open at the holding potential of À80 mV, as described. 11 Charge reversal at the same position (R198E, R198D) completely abolished voltage-dependent gating, leading to I inst /I steady-state ratios close to unity ( Fig. S2 ; Table S1 ). When compared to wild-type, K v 7.2 R198Q channels displayed slower deactivation kinetics, a result consistent with a destabilization of the closed state (Fig. 1E,  F) . Multistate molecular modeling (Fig. S3) revealed that the R198 residue is involved in electrostatic interactions with several partially negatively charged residues, including a critical cysteine (C106) in S 1 in the voltage sensor resting and close by (early activated and late deactivated) gating states, whereas no interactions seem to occur in the fully activated state, 12 suggesting the involvement of R198 in resting state voltage sensor domain (VSD) stabilization. No difference in ion selectivity 11 and tetraethylammonium (TEA) sensitivity (Table S1 ) was observed between wildtype and mutant homomeric channels. Cells transfected with K v 7.2+K v 7.2 R198Q+K v 7.3 cDNAs (0.5/0.5/1 cDNA ratio), an experimental strategy mimicking the genetic balance of the affected patients and reproducing I KM composition, 4 generated heteromeric K + currents retaining a significant 10 mV hyperpolarizing shift in their activation gating when compared to K v 7.2+K v 7.3 channels ( Fig. 1G ; Table S1 ). Finally, in cultured rat hippocampal neurons, K v 7.2 and K v 7.2 R198Q subunits (both co-expressed with K v 7.3 subunits) were similarly enriched at the ankyrin-Gidentified axon initial segments (AISs), showing identical AIS/dendrite and AIS/soma ratios (Fig. S4 ).
Discussion
We describe four patients with unremarkable neurodevelopmental status around birth, in particular, without histories of neonatal-onset seizures or encephalopathy. Each presented between ages 4 and 6 months with IS in clusters, with hypsarrhythmia at the time of EEG, accompanied by varying levels of developmental delay. Remarkably, all four patients carried the same de novo KCNQ2 variant (c. 593G>A; p.R198Q). The similarity within our small cohort strongly suggests that the shared R198Q variant, never previously reported in neonatalonset KCNQ2-related epilepsy, is pathogenic for IS, an infantile onset EE.
A KCNQ2 variant (R144Q) was previously detected by whole-gene sequencing (WES) in one of 149 patients with no apparent history of epilepsy before the onset of IS 13 ; in another cohort of 73 patients with IS, no KCNQ2 mutation was found.
14 The KCNQ2 R144Q variant was shown to exhibit GOF in heterologous expression studies. 8 Here, functional studies reveal that the K v 7.2 R198Q subunit, expressed alone or in combination with K v 7.2 and/or K v 7.3 subunits, also increases currents activated by partial membrane depolarization, without major changes in pore properties, heteromerization, maximal current density, and neuronal subcellular localization. KCNQ2 GOF is an atypical functional profile, recently described in rare patients with severe neonatal-onset epileptic encephalopathy carrying KCNQ2 R201C and R201H 13, 15 or KCNQ3 R230C 13, 16 variants. Thus, to date, two phenotypes have been associated with KCNQ2 GOF variants: a severe neonatal-onset EE (paradigmatically exhibited by R201C-carrying patients), and IS in the absence of neonatal seizures (as in R198Q patients, and the single reported R144Q patient 8, 13 ). Notably, expressed as homotetramers, R201C channels display significantly more dramatic GOF effects compared to R198Q or R144Q channels, 8, 11 making this in vitro assay a potential prognostic tool. Very recently, a different KCNQ2 variant, affecting the pore residue A306, has also been reported in a patient with sporadic IS syndrome and no apparent history of early neonatal seizures 17 ; further studies, possibly including transgenic animal models, 18 are needed to understand such complex genotype-phenotype correlations.
The limitations of retrospective chart review, limited patient numbers, the natural fluctuations in seizure frequency, and concurrent modification of multiple anticonvulsants make it difficult to draw conclusions regarding the effect, either positive or negative, of ezogabine or other anticonvulsants in patients with the R198Q variant. Although there was a perceived early positive response to ezogabine in patient 1, this was not sustained or complete, and additional anticonvulsant modifications were necessary. Similarly, response to sodium channel blockers could not be assessed. 19 Although recognized only recently, KCNQ2 encephalopathy already exhibits a diversity of apparently correlated molecular mechanisms and phenotypes. Here, identification of four unrelated patients enabled clearer conclusions to be drawn about R198Q. These finding highlight the benefits of transnational networks and multidisciplinary-curated gene-specific databases for hastening progress in phenotypic characterization, patient stratification, and individual tailoring of therapeutic approaches. 20 
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